Crescent Capital BDC, Inc. filings document the regulatory record of a business development company that invests in secured debt, unsecured debt and related equity securities of private U.S. middle-market companies. Its Form 8-K reports include operating and financial results, dividend announcements, material agreements, capital-structure disclosures and other material events.
Proxy materials describe annual meeting voting matters, board governance and director elections. The filing record also identifies the company’s registered securities, including common stock listed under CCAP and exchange-listed notes, and provides formal disclosure around governance changes, shareholder matters, risk topics and financing arrangements.
Crescent Capital BDC, Inc. (CCAP) CEO and director Jason Breaux purchased 5,000 shares of common stock at $9.98 per share on November 17, 2026. The shares were reported as directly owned by Breaux. His reported holdings after the purchase were 57,636 shares, also held directly.
Crescent Capital BDC, Inc. (CCAP) Chief Financial Officer Gerhard Lombard purchased 2,000 common shares on November 16, 2026, at a weighted average price of $10.09 per share; prices ranged from $10.06 to $10.12. He directly held 44,000 shares after the transaction, including 1,491 shares acquired through dividend reinvestment in 2026 and not previously reported pursuant to Rule 16a-11 under the Securities Act of 1934. No Rule 10b5-1 plan is reported.
Crescent Capital BDC, Inc. (CCAP) and Remora Capital Corporation entered into an amended and restated LLC agreement on November 13, 2026, to co-manage CCAP Middle Market Loan Fund, LLC, a joint venture with equal representation on its two-member board.
Each party subscribed for $30.0 million in interests. A subsidiary of the fund entered into a revolving credit facility with $140 million currently committed, secured by all of that subsidiary’s assets. Subject to approval by CCAP and Remora, the fund will initially purchase up to $150 million of assets from CCAP and is expected to invest primarily in middle market loans.
Crescent Capital BDC, Inc. (CCAP) reported third-quarter 2026 net investment income of $13.7 million, or $0.37 per share, compared with $16.9 million, or $0.46 per share, in the third quarter of 2025. Net increase in net assets from operations was $10.1 million, or $0.27 per share, compared with $7.1 million, or $0.19 per share. Net asset value was $17.72 per share at September 30, 2026.
The board declared a regular fourth-quarter 2026 cash dividend of $0.34 per share, payable January 15, 2027, to stockholders of record December 31, 2026. The third and final previously announced special dividend of $0.03 per share is payable December 15, 2026, to stockholders of record November 30, 2026.
On November 5, 2026, the board authorized repurchases of up to $50 million of common stock through an independent third-party broker under a Rule 10b5-1 trading plan. Separately, Sun Life plans to purchase up to an additional $25 million of CCAP common stock in the open market through an independent third-party broker under a Rule 10b5-1 trading plan. At September 30, CCAP had $36.2 million in cash, cash equivalents and restricted cash and $210.5 million of undrawn credit-facility capacity, subject to borrowing-base and other limitations; its net debt-to-equity ratio was 1.36x.
Crescent Capital BDC, Inc. (CCAP) lists debt and equity investments across sectors including healthcare, software, consumer services, commercial services, and financials. The debt entries include senior-secured and unitranche first-lien term loans, revolving facilities, delayed-draw loans, and unsecured debt; equity entries include common and preferred stock.
Selected listed rates are 14.00% for Halo Buyer, Inc.'s unitranche first-lien revolver and 13.34% for Affinitiv, Inc.'s unitranche first-lien term loan. Other debt terms include benchmark spreads, rate floors, and PIK components; entries also list maturities or commitment expirations.
Crescent Capital BDC, Inc. (CCAP) reported that major stockholder Fidelity & Guaranty Life Insurance Company, a ten percent owner, filed a Form 4 for open-market sales of CCAP common stock executed under a Rule 10b5-1 trading plan. On September 8, 2026, an affiliated entity sold 126,436 shares at a volume weighted average price of $10.3322 in multiple trades within a $10.285–$10.45 range. On September 9, 2026, it sold a further 139,054 shares at a volume weighted average price of $10.2288 across trades in a $10.18–$10.28 range. The shares are held by Fidelity & Guaranty Life Insurance Company of New York, a wholly owned subsidiary of the reporting person.
Crescent Capital BDC, Inc. (CCAP) reported that Fidelity & Guaranty Life Insurance Company, a ten percent owner, filed to disclose open-market sales of a total of 15,482 shares of common stock on September 3–4, 2026, executed under a Rule 10b5-1 trading plan. The shares are held through Fidelity & Guaranty Life Insurance Company of New York, a wholly owned subsidiary, and were sold in multiple transactions at volume-weighted average prices.
Crescent Capital BDC, Inc. (CCAP) has a notice of proposed sale under Rule 144 filed on behalf of Fidelity & Guaranty Life Insurance, identified as a 10% stockholder. The filing covers a proposed sale of 525,000 shares of common stock through Keefe, Bruyette & Woods on NASDAQ on or after August 24, 2026, with an aggregate market value of $5,118,750.
The notice states that Crescent Capital BDC, Inc. has 36,845,952 shares outstanding, and that the selling stockholder originally acquired 4,205,307 shares of common stock in the issuer’s November 16, 2021 initial public offering for cash.
Crescent Capital BDC, Inc. (CCAP) reported that Fidelity & Guaranty Life Insurance Company, a ten percent owner, sold a total of 56,285 shares of Common Stock in open-market or private transactions on September 1 and September 2, 2026, under a Rule 10b5-1 trading plan.
The reported sales consisted of 11,285 shares at $10.50 per share on September 1 and 45,000 shares at a volume-weighted average price of about $10.44 per share on September 2, with execution prices ranging from $10.38 to $10.59. Some of the reported holdings are owned by Fidelity & Guaranty Life Insurance Company of New York, a wholly owned subsidiary of the reporting person.
Crescent Capital BDC, Inc. (CCAP) reported that ten percent owner Fidelity & Guaranty Life Insurance Company sold shares of its common stock in late August 2026. The reporting person sold 15,000 shares on August 28, 2026 at a volume-weighted average price of $10.6020 and 40,000 shares on August 31, 2026 at a volume-weighted average price of $10.6205, both as open-market transactions under a Rule 10b5-1 trading plan. Footnotes state that the shares were sold in multiple trades within disclosed price ranges and that some shares are held through a wholly owned New York insurance subsidiary.